ICLR — ICON PLC

Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1060955 ·
Last close
$165.76
Market Cap
$12.79B
52W High
$182.97
52W Low
$99.06
ADV30
860,891
Next earnings
2026-07-29
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 2,033,999,000 477,926,000 186,997,000 104,751,000 16,319,022,000 765,164,000 7,018,726,000
Dec 2025 2,112,517,000 480,738,000 210,748,000 149,194,000 16,269,782,000 647,295,000 7,076,398,000
Sep 2025 2,042,812,000 554,448,000 258,904,000 2,355,000 16,507,490,000 468,888,000 7,172,644,000
Jun 2025 2,017,357,000 561,599,000 258,875,000 182,972,000 16,602,290,000 390,396,000 7,047,203,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,140,357,000
Investing CF
$-200,477,000
Financing CF
$-1,169,422,000
CapEx
$-176,173,000
Dividends Paid
Buybacks
$-1,149,998,000
EPS Diluted TTM
$7.39
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$2,313,835,000
Inventory
Receivables
$2,799,040,000
ST Investments
EBIT TTM
$789,963,000
Pretax Income TTM
$621,570,000
Interest Exp TTM
$168,393,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$8,270,019,072
EBITDA
$1,305,105,024
Free Cash Flow
$809,339,264
Enterprise Value
$15,824,595,968
Total Cash
$765,164,032
Total Debt
$3,542,985,984
Shares Out
77,145,378
Trailing EPS
$2.27
Book Value
$121.41
ROE
1.8%
ROA
3.5%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 8,251,340,000 1,012,459,000 229,339,000 16,269,782,000 7,076,398,000 1,036,205,000
Dec 2024 8,188,990,000 1,154,081,000 739,126,000 16,634,822,000 7,193,468,000 1,286,652,000
Dec 2023 8,054,926,000 994,230,000 554,208,000 16,864,783,000 7,653,337,000 1,161,027,000
Dec 2022 7,741,386,000 866,075,000 505,304,000 17,185,278,000 8,687,315,000 563,315,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$11.87

Max Pain — expiry 2026-08-21

max pain strike: $170.00 · spot: $165.76 · call oi: 1,698 · put oi: 2,426
Expected Move to 2026-08-21: ±$19.55 (11.79%) — implied range $146.21$185.31 · ATM straddle on $165.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $10.91B $226.58
MEDP Medpace Holdings, Inc. $16.78B $601.38
INCY INCYTE CORP $23.51B $117.67
LNTH Lantheus Holdings, Inc. $6.82B $104.82
IQV IQVIA HOLDINGS INC. $34.72B $208.05

News headlines (Yahoo Finance, 1h cache)

Icon PLC (ICLR) Up 5.8% Since Last Earnings Report: Can It Continue?
2026-07-23 15:30 · Yahoo
ICON Plc (ICLR) is Strengthening After Challenges
2026-07-22 14:40 · Yahoo
ICON Schedules Second Quarter 2026 Earnings Conference Call
2026-07-22 10:00 · Yahoo
ICON (ICLR) Stock May Be 33% Undervalued After Earnings Review Uncertainty
2026-07-09 01:12 · Yahoo
ICON Public Limited Company (ICLR) Fell Due to Uncertainty Surrounding Reported Earnings
2026-07-08 11:41 · Yahoo
Icon Reestablishes 'Credible' Path to Growth in 2027, RBC Capital Markets Says
2026-06-25 15:10 · Yahoo
Company News for Jun 25, 2026
2026-06-25 13:23 · Yahoo
Here Are Thursday’s Best Wall Street Analyst Research Calls: Brown-Forman, CoreWeave, Intel, JFrog, Keurig Dr. Pepper, Klarna Group, Qualcomm, Shift 4 Payments, and More
2026-06-25 12:08 · Yahoo
Why Icon Stock Crushed it on Wednesday
2026-06-24 21:22 · Yahoo
Icon PLC (ICLR) Q1 2026 Earnings Call Highlights: Strong Bookings and Strategic Expansions Amid ...
2026-06-24 19:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.